Cancel anytime
Artiva Biotherapeutics, Inc. Common Stock (ARTV)ARTV
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/04/2024: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -19.34% | Upturn Advisory Performance 1 | Avg. Invested days: 17 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/04/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -19.34% | Avg. Invested days: 17 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/04/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 260.36M USD |
Price to earnings Ratio - | 1Y Target Price 21.25 |
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Volume (30-day avg) 93098 | Beta - |
52 Weeks Range 9.68 - 17.31 | Updated Date 11/3/2024 |
Company Size Small-Cap Stock | Market Capitalization 260.36M USD | Price to earnings Ratio - | 1Y Target Price 21.25 |
Dividends yield (FY) - | Basic EPS (TTM) -0.93 | Volume (30-day avg) 93098 | Beta - |
52 Weeks Range 9.68 - 17.31 | Updated Date 11/3/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -111.17% | Operating Margin (TTM) -108.84% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) -44.21% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 229567183 | Price to Sales(TTM) 8.9 |
Enterprise Value to Revenue 6.8 | Enterprise Value to EBITDA - |
Shares Outstanding 24287100 | Shares Floating 4022194 |
Percent Insiders 20.64 | Percent Institutions 74.78 |
Trailing PE - | Forward PE - | Enterprise Value 229567183 | Price to Sales(TTM) 8.9 |
Enterprise Value to Revenue 6.8 | Enterprise Value to EBITDA - | Shares Outstanding 24287100 | Shares Floating 4022194 |
Percent Insiders 20.64 | Percent Institutions 74.78 |
Analyst Ratings
Rating 4.8 | Target Price 21.25 | Buy 1 |
Strong Buy 4 | Hold - | Sell - |
Strong Sell - |
Rating 4.8 | Target Price 21.25 | Buy 1 | Strong Buy 4 |
Hold - | Sell - | Strong Sell - |
About Artiva Biotherapeutics, Inc. Common Stock
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2024-07-19 | President, CEO & Director | Dr. Fred Aslan M.D. |
Sector | Healthcare | Website | https://www.artivabio.com |
Industry | Biotechnology | Full time employees | 82 |
Headquaters | San Diego, CA, United States | ||
President, CEO & Director | Dr. Fred Aslan M.D. | ||
Website | https://www.artivabio.com | ||
Website | https://www.artivabio.com | ||
Full time employees | 82 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.